Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received final approval for Zidovudine tablets in 60mg strength and tentative approval for Lamivudine tablets in 30mg – indicated for the treatment of HIV-I infection in combination with other anti-retrovirals (ARVs) – from the US Food and Drug Administration (USFDA).
Both the new drug applications are for paediatric strengths and are developed based on the United Nations’ initiative to develop paediatric formulations. With this, Aurobindo now has a total of 98 abbreviated new drug application (ANDA) approvals (70 final and 28 tentative) from the USFDA, which include 30 products in the ARV segment, the company said in a filing to the BSE on Friday.
The scrip of Aurobindo is currently trading at Rs 546 on the BSE, up 0.02 per cent as against the previous close of Rs 545.90.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app